LB11. Rapid Rise in Decreased Susceptibility to Azithromycin among Shigella Isolates in the United States: A Look at National Surveillance Data, 2011–2017

BACKGROUND: Shigella spp. cause ~500,000 illnesses in the United States annually. Antibiotics are recommended for immunocompromised patients and shorten the duration of illness, thus limiting spread. First-line treatments include ciprofloxacin (CIP) and azithromycin (AZM). CIP resistance is a growin...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Cindy, Plumb, Ian, Reynolds, Jared, Chen, Jessica, Tagg, Kaitlin, Caidi, Hayat, Watkins, Louise Francois, Karp, Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253243/
http://dx.doi.org/10.1093/ofid/ofy229.2185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253243/
http://dx.doi.org/10.1093/ofid/ofy229.2185

Ejemplares similares